• KOLs Community
    • Cluster
    • Cluster Headache
    • Peter James Goadsby
    • Peter James Goadsby

      Peter James Goadsby

      Department of Neurology, University of California, Los Angeles, Los Angeles, California, USA | National Institute for Health Research–Wellcome Trust King’s Clinical Research ...



      KOL Resume for Peter James Goadsby


      Department of Neurology, University of California, Los Angeles, Los Angeles, California, USA

      National Institute for Health Research–Wellcome Trust King’s Clinical Research Facility, King’s College Hospital, London, UK


      Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom

      Neurology, University of California Los Angeles, Los Angeles, California, USA

      NIHR-Wellcome Trust King's Clinical Research Facility, SLaM Biomedical Research Centre, King's College Hospital, London, UK

      Institute of Psychiatry, Psychology and Neuroscience, King’s College London



      Peter James Goadsby: Influence Statistics

      Sample of concepts for which Peter James Goadsby is among the top experts in the world.
      Concept World rank
      humans cluster headache #1
      dbtp patients #1
      11 years experience #1
      depression spreading depression #1
      pathophysiology treatments #1
      fewest comorbidities class #1
      naratriptan administration #1
      metaanalysis infant colic #1
      tels patients #1
      headache misdiagnosis #1
      pag stimulation stimulation #1
      palinopsia afterimages #1
      p001 nphe #1
      update pathophysiology #1
      ly2951742 migraine #1
      placebo acute treatment #1
      sinusitis delay #1
      monkey pain #1
      basic science highlights #1
      modulate trigeminovascular #1
      typical migrainous aura #1
      primary headache #1
      frovatriptan features #1
      origin techniques #1
      sumatriptan tryptamines #1
      cgrp nonheadache pain #1
      activation hypothalamus #1
      nct01952574 mmd #1
      headache exacerbation #1
      qaly total migraine #1
      patients neurologists patient #1
      model trigeminovascular #1
      secondorder neurons stimulation #1
      dilation capsaicin #1
      treatment cluster headache #1
      headache case #1
      vns mor #1
      sumatriptan trigeminal activation #1
      galcanezumab migraine headache #1
      70mg erenumab #1
      proposed definition patients #1
      gon rats #1
      tearing suna patients #1
      dural dilation #1
      vip headache #1
      arrhythmias dose verapamil #1
      placebo ly2951742 #1
      hc longterm followup #1
      orexinergic mechanisms #1
      patients ≥1 preventives #1


      Prominent publications by Peter James Goadsby

      KOL-Index: 20975

      OBJECTIVE: To evaluate and compare healthcare resource use and related costs in chronic migraine and episodic migraine in the USA and Canada.

      BACKGROUND: Migraine is a common neurological disorder that produces substantial disability for sufferers around the world. Several studies have quantified overall costs associated with migraine in general, with recent estimates ranging from $581 to $7089 per year. Although prior studies have characterized the clinical and humanistic burden of ...

      Known for Episodic Migraine | International Burden | Usa Canada | Costs Chronic | Healthcare Resource
      KOL-Index: 20419

      BACKGROUND: A substantial proportion of patients with migraine does not respond to, or cannot tolerate, oral preventive treatments. Erenumab is a novel CGRP-receptor antibody with preventive efficacy in migraine. We assessed its efficacy and tolerability in patients with episodic migraine in whom previous treatment with two-to-four migraine preventives had been unsuccessful.

      METHODS: LIBERTY was a 12-week, double-blind, placebo-controlled randomised study at 59 sites in 16 countries. ...

      Known for Episodic Migraine | Erenumab Patients | Efficacy Tolerability | Preventive Treatments | Greater Reduction
      KOL-Index: 18564

      BACKGROUND: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment for migraine. We compared two fremanezumab dose regimens with placebo for the prevention of chronic migraine.

      METHODS: In this phase 3 trial, we randomly assigned patients with chronic migraine (defined as headache of any duration or severity on ≥15 days per month and migraine on ≥8 days per month) in a 1:1:1 ratio to receive ...

      Known for Chronic Migraine | Fremanezumab Placebo | Preventive Treatment | Headache Month | Monoclonal Antibodies
      KOL-Index: 17880

      The aim of this study was to evaluate the efficacy and tolerability of topiramate for the prevention of chronic migraine in a randomized, double-blind, placebo-controlled trial. Chronic migraine is a common form of disabling headache presenting in headache subspecialty practice. Preventive treatments are essential for chronic migraine management, although there are few or no controlled empirical trial data on their use in this patient population. Topiramate is approved for the ...

      Known for Chronic Migraine | Topiramate Placebo | Controlled Study | Life Msq | Doubleblind Phase
      KOL-Index: 17644

      BACKGROUND: Rimegepant, a small molecule calcitonin gene-related peptide receptor antagonist, has shown efficacy in the acute treatment of migraine using a standard tablet formulation. The objective of this trial was to compare the efficacy, safety, and tolerability of a novel orally disintegrating tablet formulation of rimegepant at 75 mg with placebo in the acute treatment of migraine.

      METHODS: In this double-blind, randomised, placebo-controlled, multicentre phase 3 trial, adults aged ...

      Known for Acute Treatment | Rimegepant Placebo | Orally Disintegrating | Efficacy Safety | Freedom Pain
      KOL-Index: 16986

      BACKGROUND: Migraine remains poorly treated, with few effective preventive drugs available. We assessed the safety and efficacy of LY2951742, a fully humanised monoclonal antibody to calcitonin gene-related peptide, for migraine prevention.

      METHODS: We did a randomised, double-blind, placebo-controlled, phase 2 proof-of-concept study at 35 centres in the USA. Patients aged 18-65 years with four to 14 migraine headache days per month were randomly assigned (1:1) to LY2951742 or placebo by ...

      Known for Monoclonal Antibody | Calcitonin Gene | Treatment Migraine | Phase 2 | Controlled Study
      KOL-Index: 16966

      BACKGROUND: Calcitonin gene-related peptide (CGRP) is crucial in the pathophysiology of migraine. We assessed the safety, tolerability, and efficacy of ALD403, a genetically engineered humanised anti-CGRP antibody, for migraine prevention.

      METHODS: In this randomised, double-blind, placebo-controlled, exploratory, proof-of-concept phase 2 trial, patients aged 18-55 years with five to 14 migraine days per 28-day period were randomly assigned (1:1) via an interactive web response system to ...

      Known for Migraine Patients | 2 Trial | Calcitonin Gene | Placebo Patient | Adverse Event
      KOL-Index: 16656

      Lasmiditan, a serotonin 5-HT1F receptor agonist, was effective for acute treatment of patients with migraine in a phase 3 double-blind randomized controlled study. The current study was designed to replicate these findings in a generalizable population of patients with migraine, including those with a cardiovascular medical history. This prospective, double-blind, phase 3 multicentre study randomly assigned patients with migraine with and without aura (1:1:1:1 ratio) to oral lasmiditan ...

      Known for Acute Treatment | Patients Lasmiditan | Phase 3 | Pain Freedom 2 | 100 50
      KOL-Index: 16393

      OBJECTIVE: To compare the effects of oral rizatriptan, sumatriptan, naratriptan, and zolmitriptan on the relief and emergence of nausea during a migraine attack.

      METHODS: Data from five randomized, placebo-controlled, double-blind clinical trials in which oral rizatriptan 10 mg was directly compared with oral sumatriptan 100 mg (N = 772), 50 mg (N = 1168), 25 mg (N = 1180), naratriptan 2.5 mg (N = 406), or zolmitriptan 2.5 mg (N = 571) for the acute treatment of a migraine attack were ...

      Known for 2 Hours | Patients Nausea | Oral Rizatriptan | Migraine Attack | Sumatriptan 50
      KOL-Index: 15964

      BACKGROUND: We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.

      METHODS: We randomly assigned patients to receive a subcutaneous injection of either erenumab, at a dose of 70 mg or 140 mg, or placebo monthly for 6 months. The primary end point was the change from baseline to months 4 through 6 in the mean number of migraine days per month. Secondary end points were a 50% or greater ...

      Known for Erenumab Placebo | Episodic Migraine | Controlled Trial | 6 Months | Monoclonal Antibodies
      KOL-Index: 15908

      Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with cranial autonomic features (SUNA) are described, although SUNA is rarely reported. The phenotype of SUNCT and SUNA was characterized from a large series of patients (43 SUNCT, 9 SUNA). Three attack types were identified: stabs, groups of stabs and saw-tooth attacks. The mean duration of stabs was 58 s (1-600 s); stab ...

      Known for Sunct Suna | Headache Attacks | Conjunctival Injection | Lasting Unilateral | Cranial Autonomic
      KOL-Index: 15775

      Importance: Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine.

      Objective: To assess the efficacy of fremanezumab compared with placebo for prevention of episodic migraine with a monthly dosing regimen or a single higher dose.

      Design and Setting: Randomized, double-blind, placebo-controlled, parallel-group trial conducted at 123 sites in 9 countries from March 23, 2016 (first patient ...

      Known for Fremanezumab Placebo | Monthly Migraine | Baseline Week | Patients Episodic | Clinical Trial
      KOL-Index: 15167

      BACKGROUND: Atogepant is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist under investigation for treatment of migraine. We aimed to examine a range of oral doses for safety, tolerability, and efficacy for the preventive treatment of migraine.

      METHODS: In this double-blind, phase 2b/3 trial, adults (aged 18-75 years), with a history (≥1 year) of migraine and 4-14 migraine days per month, were randomly assigned 2:1:2:2:1:1 (by means of a ...

      Known for Treatment Migraine | Placebo Atogepant | 12 Weeks | Safety Tolerability | Orally Administered
      KOL-Index: 14924

      BACKGROUND: The prevalence of chronic daily headache in association with regular use of analgesics is about 2%. Whether regular use of analgesics has a causal or consequential relationship to daily headache has not been established. A causal relationship has been suggested consequent to the observation of improvement or resolution of headache following analgesic withdrawal in patients attending headache clinics, but this observation has not been validated by controlled trials.

      PURPOSE: ...

      Known for Daily Headache | 1 Patient | Aged Migraine | Analgesics Development | Tension Type

      Key People For Cluster Headache

      Top KOLs in the world
      Peter James Goadsby
      cluster headache chronic migraine acute treatment
      Arne May
      cluster headache migraine patients chronic pain
      Gennaro Bussone
      cluster headache chronic migraine medication overuse
      Anish Bahra
      cluster headache brain cancer hemicrania continua
      Karl Ekbom
      cluster headache basilar artery lifetime prevalence
      Gian Camillo Manzoni
      cluster headache chronic migraine psychiatric comorbidity

      Peter James Goadsby:Expert Impact

      Concepts for whichPeter James Goadsbyhas direct influence:Cluster headache,  Chronic migraine,  Episodic migraine,  Acute treatment,  Migraine aura,  Trigeminocervical complex,  Visual snow,  Hemicrania continua.

      Peter James Goadsby:KOL impact

      Concepts related to the work of other authors for whichfor which Peter James Goadsby has influence:Cluster headache,  Chronic migraine,  Acute treatment,  Calcitonin gene,  Nitric oxide,  Medication overuse.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Department of Neurology, University of California, Los Angeles, Los Angeles, California, USA | National Institute for Health Research–Wellcome Trust King’s Clinical Research Facility, King’s College Hospital, London, UK | Department of Neurology, Uni

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.